Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 22, 2022, the Board of Directors (the "Board") of Vicapsys Life
Sciences, Inc. (the "Company") accepted the resignations of John Potts and
Michael Yurkowsky as members of the Board, effective immediately. The
resignations were not because of a disagreement with the Company on any matter
relating to the Company's operations, policies or practices.
Also on September 22, 2022, the Board appointed each of Charles "Charlie"
Farrahar, Dr. Colleen Delaney and Richard Rosenblum as members of the Board.
Charlie Farrahar. Mr. Farrahar, age 61, is a certified public accountant with
over 30 years of managerial finance, administration, human resource, investor
relations and risk management experience in the public, private and non-profit
sectors. Mr. Farrahar served as the Company's original Chief Financial Officer
from its inception in 2014 through its merger with SSGI, Inc. to become a public
entity. He has served as Chief Financial Officer for several small biotech
startups in various stages of development and has been involved with their exits
or mergers. Currently, he serves as Chief Financial Officer for Rion LLC , a
privately held biotech company headquartered in Rochester, MN that licenses a
platform technology from Mayo Clinic. In the late 1990s, Mr. Farrahar was Chief
Financial Officer of Credit Depot Corp (Nasdaq). He was Chief Financial Officer
of Medovex Corp. when it initially went public on Nasdaq in 2014 and was Chief
Financial Officer of Roadie, Inc., when it was purchased by UPS in 2021.
Dr. Colleen Delaney. Dr. Delaney, age 55, is Scientific Founder and Chief
Scientific Officer, Executive Vice President of Research and Development of
Deverra Therapeutics, Inc., a cellular therapy company focused on development of
universal donor, off-the-shelf cell therapies for patients with hematologic
malignancies and other critical diseases. Additionally, Dr. Delaney is a stem
cell transplant physician and an Affiliate and former Professor of the Fred
Hutchinson Cancer Research Center, Clinical Research Division, where she was PI
of an NIH/government funded laboratory and where she established and became the
Director of the Program in Cord Blood Transplant and Cord Blood Research at the
Fred Hutch/Seattle Cancer Care Alliance. Dr. Delaney's research interests focus
on the development of methods to expand the number of umbilical cord blood stem
cells and to then direct these cells to further differentiate into mature blood
and immune cells for clinical application. She has more than 20 years of
experience in the development of cord blood derived allogeneic cell therapies
from bench to bedside and is an inventor on numerous patents.
Dr. Delaney received her MSc from Oxford University and her MD from Harvard
Medical School and is the recipient of numerous awards, including the
prestigious Damon Runyon Foundation Clinical Investigator Award, the Dr. Ali
Al-Johani Award in recognition of exemplary clinical medical care and compassion
to patients and families, the Seattle Business Journal's Leaders in Health Care
Award for Outstanding Medical Research and the Seattle American Women in
Science's Award for the Scientific Advancement and Leadership in STEM.
Richard Rosenblum. Mr. Rosenblum, age 63, has served as President, Chief
Financial Officer and Director of Payment Solutions Inc. since July 22, 2021.
Mr. Rosenblum has also been a member of the Board of Directors of H-Cyte since
February 1 2022. Mr. Rosenblum has been, since its founding in 1994, Chief
Executive Officer and Principal at Harborview Capital Advisors LLC, which
provided strategic advisory services in the areas of capital formation, merchant
banking and management consulting. Additionally, Mr. Rosenblum has been the
owner of Harborview Property Management for over 25 years, where he invests and
manages domestic and international commercial real-estate, and multi-family
real-estate assets. From 2008 to 2014, Mr. Rosenblum was a Director, President
and Executive Chairman of Alliqua Biomedical Inc. (NASDAQ: ALQA), which
developed and marketed hydrogel manufacturing technology in the wound care
sector. His philanthropic and community-centered activities include being a
founding board member of the Dr. David Feit Memorial Foundation, which for over
15 years raised money for the benefit and support of youth activities. Since
2018, Mr. Rosenblum has served on the Board of Directors of the Chilton Hospital
Foundation. Mr. Rosenblum graduated Summa Cum Laude from SUNY Buffalo with a
B.A. in Finance and Accounting.
We believe that Mr. Rosenblum's experience as an executive of a publicly traded
company and his financial experience, including in investment banking and as an
investor in publicly traded companies, provide him with the attributes that make
him a valuable member of the Company's Board.
© Edgar Online, source Glimpses